Navigation Links
Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
Date:8/8/2008

RICHMOND, Va., Aug. 8 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today reported results for the second quarter and six-months ended June 30, 2008.

Recent Company Highlights

-- Follow-on Biologics Program

-- Completed clinical trial demonstrating the bioequivalence of INS-19,

the company's recombinant human granulocyte colony stimulating

factor (G-CSF), to Neupogen(R), an FDA-approved G-CSF product for

the treatment of neutropenia that recorded 2007 sales of

approximately $1 billion;

-- Retained The Honorable Bill Thomas, Former Chairman of the House

Ways and Means Committee from 2001 to 2007, as a strategic advisor

to provide counsel on the Company's efforts to bring follow-on

biologics ("FOB") to U.S. consumers;

-- Retained the services of RBC Capital Markets ("RBC") to act as

Insmed's strategic financial advisor to evaluate and focus the

Company's strategic initiatives.

-- IPLEX(TM)

-- The Phase 2 trial of IPLEX(TM) in Myotonic Muscular Dystrophy

("MMD"), which was initiated in December 2007, has seen a strong

patient and physician interest and is now fully enrolled;

-- Received $2.6 million in cost recovery revenue in the second quarter

related to the expanded access program ("EAP") for IPLEX(TM). The

EAP in Italy to treat patients with Amyotrophic Lateral Sclerosis

("ALS"), also known as Lou Gehrig's Disease, currently includes 22

physicians and approximately 100 subjects have enrolled.

"Over the past several months, Insmed has achieved several important milestones across the full spectrum of its business," said Geoff Allan, President and CEO of Insmed. "Most importantly, our FOB initiatives have received strong scientific validati
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
3. Insmed to Appeal Delisting Notification From Nasdaq
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
6. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
7. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
8. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
11. Insmed to Present at CBI Follow-On Biologics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... 2015 , ... Proove Biosciences, a commercial and research ... genetics and hypertension at the International Academy of Cardiology Annual Scientific ... The event, which boasts an extensive overview of the latest research developments in ...
(Date:8/26/2015)... Aug. 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended June 30, ... Canadian dollars and presented under International Financial Reporting ... with respect to our Oral Amp B program, ... manufacturer," said Andrew Rae , President & ...
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, a ... development and manufacture of highly valued cardiac markers used in early detection of ... with protein chemistry has led to the development and commercialization of important cardiac ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic ... it has received a $1.5M Phase II SBIR ... to further develop its therapeutic agent to reduce ... need in end stage renal disease (ESRD) patients ... National Institute of Diabetes and Digestive and Kidney ...
Breaking Biology Technology:Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
... SAN DIEGO, Oct. 20 Cardium Therapeutics,(Amex: ... Inc., announced,today that it has received 510(k) clearance ... market the RapidBlue(TM) System, an endovascular,temperature modulation device. ... to manage and control patient body temperature.,This new ...
... joins Pierpoint International as Global VP of Recruitment Operations and Diversity ... ... -- Pierpoint International is pleased to announce the appointment of Robert ... most recently served as AVP of Staffing and Diversity for USAA, ...
... TorreyPines Therapeutics,Inc. (Nasdaq: TPTX ) today announced ... a Phase I multiple dose clinical trial of NGX426, ... The trial is,designed to evaluate the safety, tolerability and ... days. NGX426 has been,safely administered to more than 150 ...
Cached Biology Technology:Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 2Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 3Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 4Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 5Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 6Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 7Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 8Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 9Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular System 10Robert Cantu Appointed Vice President of Pierpoint International 2TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel 2TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel 3TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel 4
(Date:8/10/2015)... and TELTOW, Germany , August ... (SMI), a world leader in Eye Tracking Technology ... of its OEM Eye Tracking Platform for integration into ... Platform contains reference designs for seamless integration of eye ... virtual reality HMDs and augmented reality smart glasses. Omnivision,s ...
(Date:8/5/2015)... According to a new market ... Services, Vertical (BFSI, Airport, IT & Telecom, Utilities, Education, ... to 2020", published by MarketsandMarkets, defines and segments the ... segments. The global PIAM Market is estimated to grow ... 2019, at a CAGR of 14.9 % from 2014 ...
(Date:8/3/2015)... 2015 Synaptics, Inc. (Nasdaq: SYNA ), ... that members of the executive management team will present ... Technology Leadership Forum on Tuesday, August 11, 2015 at ... at the Sonnenalp Resort in Vail, CO. ... forward-looking information. An audio webcast of the event will ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... athletes looking to boost performance comes in the form of ... for its popularity is twofold says Scott Forbes, a doctoral ... for nitric oxide that is known to improve blood flow, ... to working muscles and assist with metabolic waste product removal. ...
... Bethesda, MD The Association for Molecular Pathology ... to exclusively license the subject matter of a cancer-related ... written remarks were submitted to NIH in response to ... entitled, "Prospective Grant of Exclusive License: The Development of ...
... of engineering principles to understand and treat medical conditions ... damage to the brain caused by a traumatic injury. ... presented in a special issue of Journal of ... Liebert, Inc. ( http://www.liebertpub.com ) The entire issue is ...
Cached Biology News:L-arginine: Supplement tested on fit, athletic men shows no advantage 2L-arginine: Supplement tested on fit, athletic men shows no advantage 3AMP opposes exclusive licensing of NIH proteomics patent 2Bioengineering yields new approaches for diagnosing and treating traumatic brain injury 2
... Camera hood with 5.6" TFT color screen, ... digimage system use digital camera with 8.0 mega ... space requirements and small budget. View image from ... it's specific feature. It is suitable to capture ...
... binding specificity and signaling of the members ... be modified by alternative splicing--which has important ... you can perform a classical expression profiling ... different alternatively spliced forms of the gene ...
Mouse monoclonal antibody raised against a full length recombinant CSNK2A2. NCBI Entrez Gene ID = CSNK2A2...
... Apoptosis is an evolutionarily conserved form ... cellular process. The central component of ... enzymes called caspases. These enzymes participate ... triggered in response to pro-apoptotic signals and ...
Biology Products: